Literature DB >> 10555607

Coronary heart disease is a multifactorial disease.

N Poulter1.   

Abstract

Coronary heart disease (CHD) is the leading cause of death in the Western World. For effective treatment and prevention strategies to be put in place, the major risk factors associated with this disease must be identified. Data show that almost 300 variables are statistically associated with CHD. However, evidence suggests that the vast majority of coronary events can be explained on the basis of blood pressure, lipids, smoking, and diabetes. Laboratory, experimental, and epidemiologic data identify dyslipidemia as a pivotal CHD risk factor, in the absence of which other risk factors cease to produce any important increase in absolute risk of events. For example, in populations with relatively low levels of low-density lipoprotein cholesterol, such as China and Japan, the incidence of CHD remains low even when smoking and hypertension are highly prevalent. Observational data have clearly established that CHD risk factors tend to cluster in individuals. The impact of coexisting risk factors is greater than additive, and indeed is usually multiplicative. The implications of such an interactive effect are that relatively normal levels of two or more risk factors in coexistence may have a profound impact on risk. Despite these findings, in the past most treatment algorithms have viewed risk factors separately and have recommended discrete treatment targets. More recent guidelines have taken a broader view and provide simple, yet accurate, methods of evaluating absolute risk based on the consideration of several risk factors. Coronary heart disease is clearly a multifactorial disease with risk factors that tend to cluster and interact in an individual to determine the level of coronary risk. The current trend towards a more holistic approach in CHD risk evaluation and preventive management appears logical based on evidence from animal-experimental, observational, and clinical trial evidence.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10555607     DOI: 10.1016/s0895-7061(99)00163-6

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  27 in total

1.  Gene expression profiling of coronary artery disease and its relation with different severities.

Authors:  Shiridhar Kashyap; Sudeep Kumar; Vikas Agarwal; Durga P Misra; Shubha R Phadke; Aditya Kapoor
Journal:  J Genet       Date:  2018-09       Impact factor: 1.166

Review 2.  Hypertension and lipids: lipid factors in the hypertension syndrome.

Authors:  Gary E Sander; Thomas D Giles
Journal:  Curr Hypertens Rep       Date:  2002-12       Impact factor: 5.369

Review 3.  Safe pharmacologic treatment strategies for osteoarthritis pain in African Americans with hypertension, and renal and cardiac disease.

Authors:  Jerry Johnson; Joan Weinryb
Journal:  J Natl Med Assoc       Date:  2006-07       Impact factor: 1.798

4.  Risk factors for smoking among adolescent survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Lisa S Kahalley; Leslie A Robinson; Vida L Tyc; Melissa M Hudson; Wendy Leisenring; Kayla Stratton; Ann C Mertens; Lonnie Zeltzer; Leslie L Robison; Pamela S Hinds
Journal:  Pediatr Blood Cancer       Date:  2011-05-25       Impact factor: 3.167

Review 5.  IGF-1 and cardiovascular disease.

Authors:  Yusuke Higashi; Sandeep Gautam; Patrick Delafontaine; Sergiy Sukhanov
Journal:  Growth Horm IGF Res       Date:  2019-01-31       Impact factor: 2.372

6.  A self-determination multiple risk intervention trial to improve smokers' health.

Authors:  Geoffrey C Williams; Holly McGregor; Daryl Sharp; Ruth W Kouldes; Chantal S Lévesque; Richard M Ryan; Edward L Deci
Journal:  J Gen Intern Med       Date:  2006-12       Impact factor: 5.128

7.  Deep learning for clustering of multivariate clinical patient trajectories with missing values.

Authors:  Johann de Jong; Mohammad Asif Emon; Ping Wu; Reagon Karki; Meemansa Sood; Patrice Godard; Ashar Ahmad; Henri Vrooman; Martin Hofmann-Apitius; Holger Fröhlich
Journal:  Gigascience       Date:  2019-11-01       Impact factor: 6.524

Review 8.  Cardiovascular high-risk patients--treat to protect, but whom?

Authors:  Faiez Zannad; Anne Jakobsen; Jose Heroys; Ann Ralph; Tomas Rees; Michael Shaw
Journal:  Medscape J Med       Date:  2008-03-26

9.  Study of blood flow in several benchmark micro-channels using a two-fluid approach.

Authors:  Wei-Tao Wu; Fang Yang; James F Antaki; Nadine Aubry; Mehrdad Massoudi
Journal:  Int J Eng Sci       Date:  2015-10-01       Impact factor: 8.843

10.  Treatment intensification and risk factor control: toward more clinically relevant quality measures.

Authors:  Joseph V Selby; Connie S Uratsu; Bruce Fireman; Julie A Schmittdiel; Tiffany Peng; Nicolas Rodondi; Andrew J Karter; Eve A Kerr
Journal:  Med Care       Date:  2009-04       Impact factor: 2.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.